Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Summary

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO

Timeline

Start

2021-11-11

Primary completion

2022-12-09

Completion

2022-12-09

Outcome

Outcome not reported

Stopped (Business): “Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients”

Drugs

Indications